Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$5.15 -5.3%	$5.87	$5.10 ▼ $14.36	$9.87M	0.9	17,244 shs	48,523 shs
NXTC NextCure	$5.10 -1.1%	$5.44	$2.69 ▼ $19.80	$13.69M	1.25	319,515 shs	8,007 shs
TCRT Alaunos Therapeutics	$2.25 -6.3%	$3.61	$1.31 ▼ $6.20	$3.69M	-0.81	48,371 shs	19,838 shs
UNCY Unicycive Therapeutics	$4.70 +1.5%	$5.22	$2.75 ▼ $11.00	$59.41M	1.88	382,440 shs	563,583 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	0.00%	-7.54%	-10.28%	-12.12%	-62.68%
NXTC NextCure	0.00%	+4.62%	-0.68%	-3.06%	-72.43%
TCRT Alaunos Therapeutics	0.00%	-8.91%	-30.98%	-20.77%	-7.03%
UNCY Unicycive Therapeutics	0.00%	+14.91%	+1.08%	-21.13%	+48.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLT Bolt Biotherapeutics	2.9887 of 5 stars	3.2	4.0	0.0	2.0	1.7	1.3
NXTC NextCure	4.3221 of 5 stars	3.3	3.0	4.3	2.5	1.7	1.3
TCRT Alaunos Therapeutics	1.3139 of 5 stars	0.0	5.0	0.0	3.7	0.8	0.0
UNCY Unicycive Therapeutics	2.6328 of 5 stars	3.7	2.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.33	Hold	$47.50	822.33% Upside
NXTC NextCure	2.67	Moderate Buy	$25.50	400.49% Upside
TCRT Alaunos Therapeutics	0.00	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,176.60% Upside

Current Analyst Ratings Breakdown

Latest TCRT, NXTC, UNCY, and BOLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	BOLT Bolt Biotherapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$75.00
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/20/2025	BOLT Bolt Biotherapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$7.69M	1.29	N/A	N/A	$29.89 per share	0.17
NXTC NextCure	N/A	N/A	N/A	N/A	$11.82 per share	N/A
TCRT Alaunos Therapeutics	$11K	335.45	N/A	N/A	$1.29 per share	1.74
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$63.12M	-$26.66	N/A	N/A	N/A	N/A	-83.92%	-50.11%	N/A
NXTC NextCure	-$55.65M	-$25.82	N/A	N/A	N/A	N/A	-106.62%	-85.20%	N/A
TCRT Alaunos Therapeutics	-$4.68M	-$2.46	N/A	∞	N/A	N/A	-204.94%	-142.18%	N/A
UNCY Unicycive Therapeutics	-$36.73M	-$4.12	N/A	N/A	N/A	N/A	-246.71%	-116.96%	N/A

Latest TCRT, NXTC, UNCY, and BOLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BOLT Bolt Biotherapeutics	-$6.40	-$4.46	+$1.94	-$4.46	$0.82 million	$1.80 million
8/14/2025	Q2 2025	TCRT Alaunos Therapeutics	-$5.3340	-$0.63	+$4.7040	-$0.63	N/A	N/A
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/7/2025	Q2 2025	NXTC NextCure	-$4.62	-$11.29	-$6.67	-$11.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	0.48	3.13	3.13
NXTC NextCure	N/A	3.71	3.71
TCRT Alaunos Therapeutics	N/A	1.00	1.00
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
NXTC NextCure	42.65%
TCRT Alaunos Therapeutics	27.72%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	6.10%
NXTC NextCure	17.90%
TCRT Alaunos Therapeutics	16.14%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	1.92 million	1.80 million	Not Optionable
NXTC NextCure	90	2.68 million	2.20 million	Optionable
TCRT Alaunos Therapeutics	40	1.64 million	1.38 million	No Data
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

TCRT, NXTC, UNCY, and BOLT Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

5 hours ago | globenewswire.com

Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

August 16 at 5:50 PM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 16 at 10:00 AM | prnewswire.com

Unicycive Therapeutics Raises $16.3 Million in Stock Sale

August 15 at 12:22 AM | msn.com

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

August 14 at 12:07 AM | msn.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 4:14 PM | gurufocus.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 3:55 PM | globenewswire.com

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 13, 2025 | globenewswire.com

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

August 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 11, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 9, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Holdings Lifted by Vivo Capital LLC

August 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 6, 2025 | prnewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in July

August 3, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 31, 2025 | prnewswire.com

Unicycive Therapeutics Inc Ordinary Shares UNCY - Morningstar

July 30, 2025 | morningstar.comM

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What Happened

July 30, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, NXTC, UNCY, and BOLT Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$5.15 -0.29 (-5.33%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$5.22 +0.07 (+1.46%)

As of 08/15/2025 04:20 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

NextCure NASDAQ:NXTC

$5.10 -0.06 (-1.07%)

Closing price 08/15/2025 03:47 PM Eastern

Extended Trading

$4.95 -0.14 (-2.77%)

As of 08/15/2025 07:56 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Alaunos Therapeutics NASDAQ:TCRT

$2.25 -0.15 (-6.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.26 +0.02 (+0.67%)

As of 08/15/2025 07:31 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Unicycive Therapeutics NASDAQ:UNCY

$4.70 +0.07 (+1.51%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.72 +0.02 (+0.43%)

As of 08/15/2025 07:57 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time